Dr. Jennifer M. Loftis
My Social Links

Dr. Jennifer M. Loftis

Professor
Veterans Affairs Medical Center, United State of America

Highest Degree
Ph.D. in Neuroscience and Behavior from Oregon Health & Science University, United States

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Neuroscience
62%
Psychology
90%
Psychiatry
75%
Clinical Medicine
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Wardzala, C., C. Murchison, J.M. Loftis, K.J. Schenning and N. Mattek et al., 2018. Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology, 235: 761-770.
    CrossRef  |  Direct Link  |  
  2. Walcott, A.T., M.L. Smith, J.M. Loftis and A.E. Ryabinin, 2018. Social transfer of alcohol withdrawal-induced hyperalgesia in female prairie voles. Soc. Neurosci. 10.1080/17470919.2018.1456957.
    CrossRef  |  
  3. Loftis, J.M., J. Valerio, J. Taylor, E. Huang and R. Hudson et al., 2018. S100B and inflammatory cytokine levels in blood as potential markers of blood–brain barrier damage and psychiatric impairment in comorbid hepatitis C viral infection and alcohol use disorder. Alcoholism: Clin. Exp. Res. 10.1111/acer.13796.
    CrossRef  |  
  4. Kohno, M., J.M. Loftis, M. Huckans, L.E. Dennis, H. McCready and W.F. Hoffman, 2018. The relationship between interleukin-6 and functional connectivity in methamphetamine users. Neurosci. Lett., 677: 49-54.
    CrossRef  |  Direct Link  |  
  5. Gustafsson, H.C., E.L. Sullivan, E.K. Nousen, C.A. Sullivan and E. Huang et al., 2018. Maternal prenatal depression predicts infant negative affect via maternal inflammatory cytokine levels. Brain Behav. Immunity. 10.1016/j.bbi.2018.06.011.
    CrossRef  |  
  6. Zaccari, B., W. Layne, J. Loftis and P. Penn, 2017. The participant's voice: A mixed-method evaluation of a mixed-gender seeking safety group. Alcoholism Treat. Quarterly, 35: 213-231.
    CrossRef  |  Direct Link  |  
  7. Wilhelm, C.J., B.E. Fuller, M. Huckans and J.M. Loftis, 2017. Peripheral immune factors are elevated in women with current or recent alcohol dependence and associated with altered mood and memory. Drug Alcohol Dependence, 176: 71-78.
    CrossRef  |  Direct Link  |  
  8. Huckans, M., C.J. Wilhelm, T.J. Phillips, E.T. Huang, R. Hudson and J.M. Loftis, 2017. Parallel effects of methamphetamine on anxiety and CCL3 in humans and a genetic mouse model of high methamphetamine intake. Neuropsychobiology, 75: 169-177.
    CrossRef  |  Direct Link  |  
  9. Loftis, J.M., J. Taylor, H.P. Raue, M.K. Slifka and E. Huang, 2016. Alcohol intake alters immune responses and promotes CNS viral persistence in mice. Behav. Brain Res., 312: 1-8.
    CrossRef  |  Direct Link  |  
  10. Loftis, J.M. and M.M. Lim, 2016. Sleep disturbance in substance use disorders and comorbid chronic viral infections. Addiction, 111: 1093-1094.
    CrossRef  |  Direct Link  |  
  11. Ellis, C., W. Hoffman, S. Jaehnert, J. Plagge, J.M. Loftis, D. Schwartz and M. Huckans, 2016. Everyday problems with executive dysfunction and impulsivity in adults recovering from methamphetamine addiction. Addictive Disorders Treat., 15: 1-5.
    CrossRef  |  Direct Link  |  
  12. Loftis, J.M., 2015. Commentary: Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection. Frontiers Microbiol., Vol. 6. 10.3389/fmicb.2015.00793.
    CrossRef  |  
  13. Huckans, M., B.E. Fuller, A.L. Chalker, M. Adams and J.M. Loftis, 2015. Plasma inflammatory factors are associated with anxiety, depression and cognitive problems in adults with and without methamphetamine dependence: An exploratory protein array study. Frontiers Psychiatry, Vol. 6. 10.3389/fpsyt.2015.00178.
    CrossRef  |  
  14. Huckans, M., B. Fuller, V. Wheaton, S. Jaehnert and C. Ellis et al., 2015. A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J. Psychosomatic Res., 78: 184-192.
    CrossRef  |  Direct Link  |  
  15. Loftis, J.M. and A. Janowsky, 2014. Neuroimmune Basis of Methamphetamine Toxicity. In: Review of Neurobiology: Neuroimmune Signaling in Drug Actions and Addictions, Cui, C., D. Shurtleff and R.A. Harris (Eds.). Elsevier, Oxford, UK., pp: 165-197.
  16. Huckans, M., B.E. Fuller, H. Olavarria, A.W. Sasaki and M. Chang et al., 2014. Multi‐analyte profile analysis of plasma immune proteins: Altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. Brain Behav., 4: 123-142.
    CrossRef  |  Direct Link  |  
  17. Downey, L.A. and J.M. Loftis, 2014. Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine. Eur. J. Pharmacol., 727: 125-129.
    CrossRef  |  Direct Link  |  
  18. Anacker, A.M., T.H. Ahern, C.M. Hostetler, B.D. Dufour and M.L. Smith et al., 2014. Drinking alcohol has sex-dependent effects on pair bond formation in prairie voles. Proc. Nat. Acad. Sci. 10.1073/pnas.1320879111.
    CrossRef  |  
  19. Wilhelm, C.J., D. Choi, M. Huckans, L. Manthe and J.M. Loftis, 2013. Adipocytokine signaling is altered in Flinders sensitive line rats and adiponectin correlates in humans with some symptoms of depression. Pharmacol. Biochem. Behav., 103: 643-651.
    CrossRef  |  Direct Link  |  
  20. Sakamoto, M., S.P. Woods, M. Kolessar, D. Kriz and J.R. Anderson et al., 2013. Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C. J. Neurovirol., 19: 442-451.
    CrossRef  |  Direct Link  |  
  21. Loftis, J.M., M. Huckans and S.P. Woods, 2013. Substance Abuse and Infectious Disease. In: Neuropsychological Aspects of Substance Use Disorders: Evidence-Based Perspectives, Allen, D.N. and S.P. Woods (Eds.)., Oxford University Press, New York.
  22. Loftis, J.M., C.J. Wilhelm, A.A. Vandenbark and M. Huckans, 2013. Partial MHC/neuroantigen peptide constructs: A potential neuroimmune-based treatment for methamphetamine addiction. PloS One, Vol. 8. 10.1371/journal.pone.0056306.
    CrossRef  |  
  23. Loftis, J.M., C.J. Wilhelm and M. Huckans, 2013. Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: An 8-week, randomized, double-blind, placebo-controlled study. Therapeutic Adv. Psychopharmacol., 3: 21-27.
    CrossRef  |  Direct Link  |  
  24. Loftis, J.M., A.L. Patterson, C.J. Wilhelm, H. McNett and B.J. Morasco et al., 2013. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study. J. Psychosomatic Res., 74: 57-63.
    CrossRef  |  Direct Link  |  
  25. Loftis, J.M., 2013. Indolamine 2, 3-dioxygenase regulation and neuropsychiatric symptoms. Psychoneuroendocrinology, 38: 1829-1830.
    CrossRef  |  Direct Link  |  
  26. Loftis, J.M. and P. Hauser, 2013. Pain and opioid use in chronic liver disease: Optimal treatment must address the mental health care needs of the patient. Digestive Dis. Sci., 58: 2753-2755.
    CrossRef  |  Direct Link  |  
  27. Loftis, J.M. and M. Huckans, 2013. Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy. Pharmacol. Therapeutics, 139: 289-300.
    CrossRef  |  Direct Link  |  
  28. Wilhelm, C.J., A. Murphpy-Crews, D.J. Menasco, M. Huckans and J.M. Loftis, 2012. CRF1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1β treatment. Neuropharmacology, 62: 313-321.
    CrossRef  |  
  29. Hostetler, C.M., A.M. Anacker, J.M. Loftis and A.E. Ryabinin, 2012. Social housing and alcohol drinking in male-female pairs of prairie voles (Microtus ochrogaster). Psychopharmacology, 224: 121-132.
    CrossRef  |  Direct Link  |  
  30. Patterson, A.L., B.J. Morasco, B.E. Fuller, D.W. Indest, J.M. Loftis and P. Hauser, 2011. Screening for depression in patients with hepatitis C using the beck depression inventory-II: Do somatic symptoms compromise validity? Gen. Hospital Psychiatry, 33: 354-362.
    CrossRef  |  Direct Link  |  
  31. Lotrich, F.E., J.M. Loftis, R.E. Ferrell, M. Rabinovitz and P. Hauser, 2011. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J. Interferon Cytokine Res., 31: 331-336.
    CrossRef  |  
  32. Loftis, J.M., D. Choi, W. Hoffman and M.S. Huckans, 2011. Methamphetamine causes persistent immune dysregulation: A cross-species, translational report. Neurotoxicity Res., 20: 59-68.
    CrossRef  |  Direct Link  |  
  33. Loftis, J.M., B.J. Morasco and P. Hauser, 2011. Depression and antiviral response to interferon‐based therapy for hepatitis C virus infection. Hepatology, 53: 1413-1414.
  34. Loftis, J.M., 2011. Sertoli cell therapy: A novel possible treatment strategy for treatment-resistant major depressive disorder. Med. Hypotheses, 77: 35-42.
    CrossRef  |  Direct Link  |  
  35. Loftis, J.M. and M. Huckans, 2011. Cognitive enhancement in combination with ‘brain repair’may be optimal for the treatment of stimulant addiction. Addiction, 106: 1021-1022.
    CrossRef  |  Direct Link  |  
  36. Huckans, M., A. Seelye, J. Woodhouse, T. Parcel and L. Mull et al., 2011. Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C. J. Clin. Exp. Neuropsychol., 33: 176-186.
    CrossRef  |  Direct Link  |  
  37. Huckans, M. and J.M. Loftis, 2011. Handbook of medical neuropsychology: Add it to your library. J. Clin. Exp. Neuropsychol., 24: 1-3.
  38. Anacker, A.M., J.M. Loftis, S. Kaur and A.E. Ryabinin, 2011. Prairie voles as a novel model of socially facilitated excessive drinking. Addiction Biol., 16: 92-107.
    CrossRef  |  Direct Link  |  
  39. Anacker, A.M., J.M. Loftis and A.E. Ryabinin, 2011. Alcohol intake in prairie voles is influenced by the drinking level of a peer. Alcoholism: Clin. Exp. Res., 35: 1884-1890.
    CrossRef  |  Direct Link  |  
  40. Morasco, B.J., M. Huckans, J.M. Loftis, J. Woodhouse, A. Seelye, D.C. Turk and P. Hauser, 2010. Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. Gen. Hospital Psychiatry, 32: 413-418.
    CrossRef  |  Direct Link  |  
  41. Morasco, B.J., J.M. Loftis, D.W. Indest, S. Ruimy, J.W. Davison, B. Felker and P. Hauser, 2010. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: A double-blind, placebo-controlled trial. Psychosomatics, 51: 401-408.
    CrossRef  |  Direct Link  |  
  42. Loftis, J.M., M. Huckans and B.J. Morasco, 2010. Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies. Neurobiol. Dis., 37: 519-533.
    CrossRef  |  Direct Link  |  
  43. Loftis, J.M., B.J. Morasco, D. Menasco, D. Fuchs, M. Strater and P. Hauser, 2010. Serum serotonin levels are associated with antiviral therapy outcomes in patients with chronic hepatitis C. Open Infect. Dis. J., 4: 132-141.
    Direct Link  |  
  44. Loftis, J.M. and E.H. Turner, 2010. Novel treatment strategies for depression in patients with hepatitis C. Psychosomatics, 51: 357-358.
    CrossRef  |  Direct Link  |  
  45. Huckans, M., A. Mitchell, S. Pavawalla, B. Morasco and S. Ruimy et al., 2010. The influence of antiviral therapy on psychiatry symptoms among hepatitis C patients with schizophrenia. Antiviral Therapy, 15: 111-119.
  46. Mansour, H.A., M.E. Talkowski, J. Wood, K.V. Chowdari and L. McClain et al., 2009. Association study of twenty-one circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Bipolar Disorders, 11: 701-710.
  47. Huckans, M., A. Seelye, T. Parcel, L. Mull and J. Woodhouse et al., 2009. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. J. Int. Neuropsychol. Soc., 15: 69-82.
    CrossRef  |  
  48. Hauser, P., B.J. Morasco, A. Linke, D. Bjornson and S. Ruimy et al., 2009. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics, 50: 500-505.
    CrossRef  |  Direct Link  |  
  49. Fuller, B.E., J.M. Loftis, V.L. Rodriguez, M.J. McQuesten and P. Hauser, 2009. Psychiatric and substance use disorders comorbidities in veterans with hepatitis C virus and HIV coinfection. Curr. Opinion Psychiatry, 22: 401-408.
    CrossRef  |  Direct Link  |  
  50. Nelligan, J.A., J.M. Loftis, A.M. Matthews, B.L. Zucker, A.M. Linke and P. Hauser, 2008. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: Results from a retrospective chart review. J. Clin. Psychiatry, 69: 810-816.
    CrossRef  |  Direct Link  |  
  51. Loftis, J.M., M. Huckans, S. Ruimy, D.J. Hinrichs and P. Hauser, 2008. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1β and tumor necrosis factor-α. Neurosci. Lett., 430: 264-268.
    CrossRef  |  Direct Link  |  
  52. Loftis, J.M. and P. Hauser, 2008. Risk and protective factors in interferon-induced depression: treatment strategies and clinical outcomes. Directions Psychiatry, 28: 227-242.
  53. Loftis, J.M. and P. Hauser, 2008. Prevalence of psychiatric and substance use disorder comorbidities in patients with hepatitis C. Psychiatry, 28: 211-225.
  54. Huckans, M., A. Mitchell, S. Ruimy, J. Loftis and P. Hauser, 2008. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophrenia Bull., 36: 165-172.
    CrossRef  |  Direct Link  |  
  55. Morasco, B.J., M.A. Rifai, J.M. Loftis, D.W. Indest, J.K. Moles and P. Hauser, 2007. A randomized trial of paroxetine to prevent interferon-α-induced depression in patients with hepatitis C. J. Affective Disorders, 103: 83-90.
    CrossRef  |  Direct Link  |  
  56. Huckans, M.S., J.M. Loftis, A.D. Blackwell and P. Hauser, 2007. Interferon-based therapy for hepatitis C: Treatment response and completion rates among patients with schizophrenia, schizoaffective disorder and substance use disorder. Substance Abuse Treat. Prevention Policy, 12: 2-4.
  57. Turner, E.H., J.M. Loftis and A.D. Blackwell, 2006. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Therapeutics, 109: 325-338.
    CrossRef  |  Direct Link  |  
  58. Rifai, M.A., J.M. Loftis and P. Hauser, 2006. Hepatitis C treatment of veterans with psychiatric illness. Am. J. Gastroenterol., 101: 673-674.
    Direct Link  |  
  59. Rifai, M.A., D. Indest, J. Loftis and P. Hauser, 2006. Psychiatric management of the hepatitis C patient. Curr. Treat. Options Gastroenterol., 9: 508-519.
    CrossRef  |  Direct Link  |  
  60. Loftis, J.M., P. Hauser, T.A. Macey and J.D. Lowe, 2006. Can rodents be used to model interferon-α-induced depressive symptoms? Progr. Neuropsychopharmacol. Biol. Psychiatry, 7: 1364-1365.
  61. Loftis, J.M., J.M. Wall, R.L. Pagel and P. Hauser, 2006. Administration of pegylated interferon-does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology, 31: 1289-1294.
  62. Loftis, J.M., A.M. Matthews and P. Hauser, 2006. Psychiatric and substance use disorders in individuals with hepatitis C. Drugs, 66: 155-174.
    CrossRef  |  Direct Link  |  
  63. Rifai, M.A., J.M. Loftis and P. Hauser, 2005. Interferon-treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment. CNS Drugs, 19: 719-721.
  64. Mansour, H.A., M.E. Talkowski, J. Wood, L. Pless and M. Bamne et al., 2005. Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. Ann. Med., 37: 590-602.
    CrossRef  |  Direct Link  |  
  65. Loftis, J.M., M.A. Rifai and P. Hauser, 2005. The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav. Immunity, 19: 271-272.
    CrossRef  |  
  66. Loftis, J.M. and P. Hauser, 2005. Letter to the editor re: The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complication in chronic hepatitis C. Hum. Psychopharmacol.: Clin. Exp., 20: 211-212.
  67. Sylvestre, D.L., J.M. Loftis, P. Hauser, S. Genser and H. Cesari et al., 2004. Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care. J. Urban Health, 81: 719-734.
    CrossRef  |  Direct Link  |  
  68. Loftis, J.M., R.E. Socherman, C.D. Howell, A.J. Whitehead, J.A. Hill, J.A. Dominitz and P. Hauser, 2004. Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C. Neurosci. Lett., 365: 87-91.
    CrossRef  |  Direct Link  |  
  69. Loftis, J.M., J.M. Wall, E. Linardatos, S. Benvenga and P. Hauser, 2004. A quantitative assessment of depression and thyroid dysfunction secondary to antiviral therapy in patients with hepatitis C. J. Endocrinol. Invest., 27: RC16-RC20.
  70. Loftis, J.M. and P. Hauser, 2004. The phenomenology and treatment of interferon-induced depression. J. Affective Disorders, 82: 175-190.
    CrossRef  |  Direct Link  |  
  71. Hauser, P., J.M. Loftis, E. Dieperink, G. Garcia-Tsao, M. Rigsby and M. Willenbring, 2004. Depression and substance use disorders in chronic hepatitis C: Implications of new guidelines and experience in the VA health care system. Federal Practitioner, 21: 90-102.
  72. Loftis, J.M. and P. Hauser, 2003. Safety considerations for the treatment of interferon-induced depression. Psychosomatics, 44: 524-526.
  73. Loftis, J.M. and P. Hauser, 2003. Hepatitis C in patients with psychiatric disease and substance abuse: Screening strategies and comanagement models of care. Curr. Hepatitis Rep., 2: 93-100.
    CrossRef  |  Direct Link  |  
  74. Loftis, J.M. and P. Hauser, 2003. Co-management of depression and HCV treatment. Psychiatric Ann., 33: 385-391.
  75. Loftis, J.M. and A. Janowsky, 2003. Review of the NMDA receptor, NR2B: localization, functional properties, regulation and clinical implications. Pharmacol. Therapeutics, 97: 55-85.
  76. Loftis, J.M. and A. Janowsky, 2002. Cocaine-withdrawal induced alterations in the expression and serine phosphorylation of the NR1 NMDA receptor subunit. Psychopharmacology, 164: 349-359.
  77. Mason, J.N., A.J. Eshleman, J.K. Belknap, J.C. Crabbe, J.M. Loftis, T.A. Macey and A. Janowsky, 2001. NMDA receptor subunit mRNA and protein expression in ethanol‐withdrawal seizure‐prone and‐resistant mice. Alcoholism: Clin. Exp. Res., 25: 651-660.
    CrossRef  |  Direct Link  |  
  78. Loftis, J.M. and A. Janowsky, 2000. Regulation of NMDA receptor subunits and nitric oxide synthase expression during cocaine withdrawal. J. Neurochem., 75: 2040-2050.
    CrossRef  |  Direct Link  |  
  79. Fridlund, A.J. and J.M. Loftis, 1990. Relationship between tickling and humorous laughter. Biol. Psychol., 30: 141-150.